Paeoniflorigenone inhibits the progression of cholangiocarcinoma via HIF1A and enhances the chemotherapy sensitivity of cisplatin

Key Points

• Paeoniflorigenone significantly inhibits the progression of cholangiocarcinoma, with a notable impact on cell viability.
• Treatment with paeoniflorigenone demonstrates a 40% increase in chemotherapy sensitivity to cisplatin in vitro.
• Assessment using in vitro models highlights the interaction between paeoniflorigenone and HIF1A pathways in cholangiocarcinoma cells.
• These findings may enable new treatment strategies that combine paeoniflorigenone with standard chemotherapy.